QQQ   296.36 (+1.03%)
AAPL   146.24 (+1.58%)
MSFT   248.07 (+0.03%)
META   151.55 (+2.89%)
GOOGL   99.32 (+1.85%)
AMZN   102.14 (+2.94%)
TSLA   178.28 (+11.24%)
NVDA   203.61 (+2.82%)
NIO   12.72 (+4.52%)
BABA   118.29 (-1.89%)
AMD   75.56 (+0.53%)
T   19.92 (-0.40%)
MU   63.94 (+1.82%)
F   13.27 (+2.71%)
CGC   2.92 (+5.80%)
GE   83.38 (+2.76%)
DIS   109.58 (-0.11%)
AMC   5.51 (+4.36%)
PFE   43.89 (-0.81%)
PYPL   81.86 (+1.30%)
NFLX   360.94 (-1.08%)
QQQ   296.36 (+1.03%)
AAPL   146.24 (+1.58%)
MSFT   248.07 (+0.03%)
META   151.55 (+2.89%)
GOOGL   99.32 (+1.85%)
AMZN   102.14 (+2.94%)
TSLA   178.28 (+11.24%)
NVDA   203.61 (+2.82%)
NIO   12.72 (+4.52%)
BABA   118.29 (-1.89%)
AMD   75.56 (+0.53%)
T   19.92 (-0.40%)
MU   63.94 (+1.82%)
F   13.27 (+2.71%)
CGC   2.92 (+5.80%)
GE   83.38 (+2.76%)
DIS   109.58 (-0.11%)
AMC   5.51 (+4.36%)
PFE   43.89 (-0.81%)
PYPL   81.86 (+1.30%)
NFLX   360.94 (-1.08%)
QQQ   296.36 (+1.03%)
AAPL   146.24 (+1.58%)
MSFT   248.07 (+0.03%)
META   151.55 (+2.89%)
GOOGL   99.32 (+1.85%)
AMZN   102.14 (+2.94%)
TSLA   178.28 (+11.24%)
NVDA   203.61 (+2.82%)
NIO   12.72 (+4.52%)
BABA   118.29 (-1.89%)
AMD   75.56 (+0.53%)
T   19.92 (-0.40%)
MU   63.94 (+1.82%)
F   13.27 (+2.71%)
CGC   2.92 (+5.80%)
GE   83.38 (+2.76%)
DIS   109.58 (-0.11%)
AMC   5.51 (+4.36%)
PFE   43.89 (-0.81%)
PYPL   81.86 (+1.30%)
NFLX   360.94 (-1.08%)
QQQ   296.36 (+1.03%)
AAPL   146.24 (+1.58%)
MSFT   248.07 (+0.03%)
META   151.55 (+2.89%)
GOOGL   99.32 (+1.85%)
AMZN   102.14 (+2.94%)
TSLA   178.28 (+11.24%)
NVDA   203.61 (+2.82%)
NIO   12.72 (+4.52%)
BABA   118.29 (-1.89%)
AMD   75.56 (+0.53%)
T   19.92 (-0.40%)
MU   63.94 (+1.82%)
F   13.27 (+2.71%)
CGC   2.92 (+5.80%)
GE   83.38 (+2.76%)
DIS   109.58 (-0.11%)
AMC   5.51 (+4.36%)
PFE   43.89 (-0.81%)
PYPL   81.86 (+1.30%)
NFLX   360.94 (-1.08%)
NASDAQ:GNFT

Genfit - GNFT Stock Forecast, Price & News

$4.36
+0.18 (+4.31%)
(As of 01/27/2023 04:02 PM ET)
Add
Compare
Today's Range
$4.16
▼
$4.36
50-Day Range
$3.53
▼
$4.39
52-Week Range
$3.02
▼
$5.05
Volume
4,964 shs
Average Volume
10,265 shs
Market Capitalization
$217.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Genfit MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
129.4% Upside
$10.00 Price Target
Short Interest
Bearish
0.25% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.81) to ($0.07) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.74 out of 5 stars

Medical Sector

880th out of 1,055 stocks

Biological Products, Except Diagnostic Industry

142nd out of 170 stocks

See Top Rated MarketRank™ Stocks Here

GNFT stock logo

About Genfit (NASDAQ:GNFT) Stock

Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver. The company was founded by Jean-François Mouney, Florence Séjourné, and Bart Staels in September 1999 and is headquartered in Loos, France.

Receive GNFT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genfit and its competitors with MarketBeat's FREE daily newsletter.

GNFT Stock News Headlines

January 5, 2023 | finance.yahoo.com
GENFIT to Participate in Upcoming Investor Conferences
October 10, 2022 | benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session - Acer Therapeutics (NASDAQ:ACER), Avadel Pha - Benzinga
January 27, 2023 | Porter & Company (Ad)
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
September 30, 2022 | globenewswire.com
GENFIT Announces Signature of the Share Purchase Agreement and the Completion of its Acquisition of Versantis - GlobeNewswire
September 28, 2022 | globenewswire.com
GENFIT Reports First Half-Year 2022 Financial Results and Provides Corporate Update - GlobeNewswire
September 19, 2022 | finance.yahoo.com
Genfit To Buy This Swiss Firm Expanding Its Portfolio in Liver Diseases - Yahoo Finance
September 19, 2022 | finance.yahoo.com
Genfit To Buy This Swiss Firm Expanding Its Portfolio in Liver Diseases
September 19, 2022 | uk.finance.yahoo.com
Nicox Announces Last Patients Complete Final Visit in NCX 470 Phase 3 Mont Blanc Glaucoma Trial - Yahoo Finance UK
January 27, 2023 | Porter & Company (Ad)
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
September 19, 2022 | seekingalpha.com
Genfit to acquire Swiss-based Versantis in liver diseases biotech (NASDAQ:GNFT) - Seeking Alpha
September 19, 2022 | globenewswire.com
GENFIT to Acquire Clinical-stage Biopharmaceutical Company Versantis, expanding its Portfolio in Liver Diseases - GlobeNewswire
September 13, 2022 | benzinga.com
Genfit (NASDAQ:GNFT) – GENFIT Announces FDA Has Granted Orphan Drug Designation To GNS5611, For The Treat - Benzinga
September 13, 2022 | globenewswire.com
FDA Grants GENFIT's GNS561 Orphan Drug Designation for the - GlobeNewswire
September 12, 2022 | streetinsider.com
GenSight Biologics Strengthens Its Management Team to Support the Launch of LUMEVOQ® in Europe - StreetInsider.com
September 7, 2022 | seekingalpha.com
Genfit S.A.: A 'Sum Of The Parts' Story (NASDAQ:GNFT) - Seeking Alpha
September 4, 2022 | reuters.com
GNFT.PA - Genfit SA | Stock Price & Latest News | Reuters
August 19, 2022 | benzinga.com
Analyzing Genfit's Short Interest - Benzinga
August 18, 2022 | streetinsider.com
SELLAS Life Sciences (SLS) Appoints Katherine Bach Kalin to its Board - StreetInsider.com
August 16, 2022 | finance.yahoo.com
SELLAS Life Sciences’ Announces Election of Katherine Bach Kalin to its Board of Directors - Yahoo Finance
July 29, 2022 | businesswire.com
Non-alcoholic Steatohepatitis Biomarkers Market Analysis: Hepatic Fibrosis, Serum, Oxidative Stress, Apoptosis - Global Forecast to 2029 - ResearchAndMarkets.com - Business Wire
July 8, 2022 | barrons.com
Intercept Will Ask Yet Again for FDA to Approve Its NASH Drug - Barron's
July 8, 2022 | rttnews.com
Pre-market Movers: DBD, SRG, ISIG, UPST, CSSE… - RTTNews
June 22, 2022 | globenewswire.com
Nonalcoholic Steatohepatitis Therapeutics Market Expands with Rising Cases of Obesity and Diabetes, States TMR Report - GlobeNewswire
June 14, 2022 | seekingalpha.com
Gelesis, Entrada top healthcare gainers; Outset Medical, Arcellx lead losers' pack - Seeking Alpha
June 8, 2022 | nasdaq.com
Pre-market Movers: XCUR, CYRN, EFOI, NVAX, AERC… - Nasdaq
May 25, 2022 | finance.yahoo.com
GENFIT: May 25, 2022 Combined Shareholders Meeting results - Yahoo Finance
May 12, 2022 | finance.yahoo.com
GENFIT Reports First Quarter 2022 Financial Information (Unaudited financial information under IFRS) - Yahoo Finance
See More Headlines
Receive GNFT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genfit and its competitors with MarketBeat's FREE daily newsletter.

GNFT Company Calendar

Today
1/27/2023
Next Earnings (Estimated)
4/06/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GNFT
CUSIP
N/A
CIK
1757064
Web
www.genfit.com
Phone
(332) 016-4000
Fax
N/A
Employees
122
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.00
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+129.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.66
Current Ratio
6.33
Quick Ratio
6.33

Sales & Book Value

Annual Sales
$101.25 million
Price / Sales
2.15
Cash Flow
$1.68 per share
Price / Cash Flow
2.60
Book Value
$2.83 per share
Price / Book
1.54

Miscellaneous

Outstanding Shares
49,835,000
Free Float
47,742,000
Market Cap
$217.28 million
Optionable
Not Optionable
Beta
1.28

Key Executives

  • Pascal Prigent
    Chief Executive Officer
  • Pascal Caisey
    Chief Operating Officer
  • Thomas Baetz
    Chief Financial Officer
  • Dean W. Hum
    Chief Scientific Officer
  • Carol L. Addy
    Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Institutional Transactions













GNFT Stock - Frequently Asked Questions

Should I buy or sell Genfit stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genfit in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" GNFT shares.
View GNFT analyst ratings or view top-rated stocks.

What is Genfit's stock price forecast for 2023?

1 Wall Street analysts have issued 12 month target prices for Genfit's shares. Their GNFT share price forecasts range from $10.00 to $10.00. On average, they expect the company's stock price to reach $10.00 in the next year. This suggests a possible upside of 139.2% from the stock's current price.
View analysts price targets for GNFT or view top-rated stocks among Wall Street analysts.

How have GNFT shares performed in 2023?

Genfit's stock was trading at $4.3890 at the start of the year. Since then, GNFT shares have decreased by 4.8% and is now trading at $4.18.
View the best growth stocks for 2023 here.

When is Genfit's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 6th 2023.
View our GNFT earnings forecast.

What is Jean-François Mouney's approval rating as Genfit's CEO?

3 employees have rated Genfit Chief Executive Officer Jean-François Mouney on Glassdoor.com. Jean-François Mouney has an approval rating of 29% among the company's employees. This puts Jean-François Mouney in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Genfit own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genfit investors own include Intercept Pharmaceuticals (ICPT), InterDigital (IDCC), STAG Industrial (STAG), Gilead Sciences (GILD), Occidental Petroleum (OXY), Vaxart (VXRT), Exxon Mobil (XOM), Zynerba Pharmaceuticals (ZYNE), Aimmune Therapeutics (AIMT) and Amarin (AMRN).

When did Genfit IPO?

(GNFT) raised $132 million in an initial public offering on Wednesday, March 27th 2019. The company issued 5,000,000 shares at a price of $26.33 per share. SVB Leerink and Barclays served as the underwriters for the IPO and Bryan, Garnier, Natixis, Roth Capital Partners and H.C. Wainwright & Co. were co-managers.

What is Genfit's stock symbol?

Genfit trades on the NASDAQ under the ticker symbol "GNFT."

How do I buy shares of Genfit?

Shares of GNFT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Genfit's stock price today?

One share of GNFT stock can currently be purchased for approximately $4.18.

How much money does Genfit make?

Genfit (NASDAQ:GNFT) has a market capitalization of $208.31 million and generates $101.25 million in revenue each year.

How many employees does Genfit have?

The company employs 122 workers across the globe.

How can I contact Genfit?

Genfit's mailing address is PARC 885 AVENUE EUGENE AVINEE, LOOS I0, 59120. The official website for the company is www.genfit.com. The company can be reached via phone at (332) 016-4000 or via email at investors@genfit.com.

This page (NASDAQ:GNFT) was last updated on 1/27/2023 by MarketBeat.com Staff